JAK Inhibitors for Alopecia Areata

How Can an Arthritis Drug Treat Alopecia Areata?

Alopecia areata develops when immune cells mistakenly target growing hair follicles, causing sharply defined patches of hair loss or, in severe cases, loss across the scalp and body. Several inflammatory signals involved in this attack travel through the Janus kinase, or JAK, pathway. Blocking that pathway can reduce immune activity around follicles and allow hair growth to resume while treatment continues.

Baricitinib was initially developed for rheumatoid arthritis and later became the first systemic treatment authorized by the FDA for adults with severe alopecia areata. Ritlecitinib, which inhibits JAK3 and members of the TEC kinase family, is approved for severe disease in adults and adolescents aged 12 years and older. Other arthritis medicines being studied for hair loss remain investigational unless regulators specifically authorize that use.

What Evidence Supports JAK Inhibitors for Hair Regrowth?

The BRAVE-AA1 and BRAVE-AA2 phase 3 trials evaluated baricitinib against placebo in adults with severe alopecia areata. Published in The New England Journal of Medicine, the trials found that baricitinib increased the likelihood of reaching substantial scalp-hair coverage after 36 weeks. These controlled studies supported its FDA approval and established JAK inhibition as an evidence-based systemic treatment strategy.

Results vary considerably between patients. Some experience marked regrowth, whereas others obtain little benefit, and eyebrows, eyelashes or nails may respond differently from scalp hair. Treatment does not eliminate the underlying autoimmune tendency, and hair loss can return after therapy is discontinued. Longer-term monitoring remains important for understanding durability, maintenance dosing and uncommon adverse effects.

What Are the Safety Risks of Alopecia Areata JAK Inhibitors?

Systemic JAK inhibitors affect immune signaling throughout the body rather than only around hair follicles. FDA prescribing information warns about serious infections and other potentially severe harms, including malignancy, major cardiovascular events and thrombosis. The relevance of each risk depends on the specific medicine and the patient's age, smoking history, cardiovascular health, infection exposure and other medical conditions.

Clinicians generally screen for tuberculosis and viral hepatitis, review vaccination status and obtain appropriate laboratory tests before and during treatment. Patients should promptly report fever, persistent cough, shingles symptoms, chest pain, breathing difficulty or unilateral leg swelling. For limited disease, local treatments such as corticosteroids may remain appropriate; oral therapy is generally considered when hair loss is extensive or has a major effect on daily life.